Labetalol Hepatotoxicity
Authors: J A Clark, H J Zimmerman, L A Tanner
Journal: Annals of Internal Medicine (1990)

Articles1 August 1990Labetalol HepatotoxicityJohn A. Clark, MD, MSPH, Hyman J. Zimmerman, MD, Lelia Ann Tanner, RPhJohn A. Clark, MD, MSPH, Hyman J. Zimmerman, MD, Lelia Ann Tanner, RPhAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-3-210 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe Food and Drug Administration has received 11 reports of cases (three fatal) in the United States in which hepatocellular damage was associated with labetalol. The temporal circumstances strongly implicate labetalol; the conditions of nine patients improved after cessation of labetalol therapy, and one patient had a recurrence after therapy was restarted. Follow-up with each reporting physician failed to provide historic or laboratory evidence for other viral, toxic, or drug-induced causes of hepatocellular damage, and the case series did not show the demographic and historic risk factors that would be expected if non-A, non-B hepatitis were the cause. Reports of microscopic liver examinations were available in the 5 cases in which they were done. The reported histologic changes were consistent with hepatocellular necrosis in four instances and chronic active hepatitis in one. The clinical presentation of the cases was most compatible with the mechanism of metabolic idiosyncracy, but other pathogenetic explanations could not be entirely excluded....References1. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. New York: Appleton-Century-Crofts; 1978. Google Scholar2. OlmosGumaColombatoLamiMiyashiroAlvarez MCLGRE. Hepatic lesions induced by drugs. Report of 26 cases. Acta Gastroenterol Latinoam. 1987; 17:105-11. MedlineGoogle Scholar3. DouglasYangJensenThiele DRPD. Fatal labetalol-induced hepatic injury. Am J Med. 1989;87:235-6. CrossrefMedlineGoogle Scholar4. Forster H. Hepatitis from hydralazine [Letter]. N Engl J Med. 1980;302:1362. CrossrefMedlineGoogle Scholar5. ItohIchinoeTsukadaItoh SAYY. Hydralazine-induced hepatitis. Hepatogastroenterology. 1981;28:13-6. MedlineGoogle Scholar6. Dienstag J. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology. 1983;85:439-62. CrossrefMedlineGoogle Scholar7. AlterGeretySmallwood MRL. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U. S. population. J Infect Dis. 1982;145:886-93. CrossrefMedlineGoogle Scholar8. AlterColemanAlexander MPW. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989;262:1201-5. CrossrefMedlineGoogle Scholar9. SeggieSaundersKirsch JSR. Patterns of hepatic injury induced by methyldopa. S Afr Med J. 1979;55:75-83. MedlineGoogle Scholar10. LarreyHenrionHeller DJF. Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping. Ann Intern Med. 1988; 108:67-8. LinkGoogle Scholar11. RodmanDeutschGutman JDS. Methyldopa hepatitis: a report of six cases and review of the literature. Am J Med. 1976;60:941-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the Food and Drug Administration, Rockville, Maryland; and the Armed Forces Institute of Pathology, Washington, DC. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPharmacologic Control of Blood Pressure in Infants and ChildrenDrug-induced liver injury in pregnancyLabetalol-Induced Hepatotoxicity during Pregnancy: A Case Reportα1-and β-adrenergic antagonist labetalol induces morphological changes in human erythrocytesDrug-Induced Liver InjuryUse of Antihypertensive Drugs During PreeclampsiaDrug-Induced Liver InjuryHypertension in PregnancyDrugs and ToxinsLabetalolDrug-induced fulminant hepatic failure in pregnancyHepatitis tóxica hepatocelular por labetalolBeta-BlockersCardiac Drugs During Pregnancy and LactationHepatotoxicity of Cardiovascular and Antidiabetic DrugsDrug-Induced Liver InjuryHepatic injury due to drugs, herbal compounds, chemicals and toxinsDrug-Induced Liver InjuryDrug-Induced Liver DiseaseDrug-Induced Liver InjuryThe management of hypertensive emergencies in children after stem cell transplantationAntihypertensives and ProstanoidsThe existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reportsLiver Disease Caused by DrugsAtenolol Hepatotoxicity: Report of a Complicated CaseDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisDrug-induced liver injury: Is it somehow foreseeable?Fatal intoxication with labetalol (Trandate®)Assessment of Drug−Lipid Complex Formation by a High-Throughput Langmuir-Balance and Correlation to PhospholipidosisProbable Labetalol-Induced HepatotoxicityHypertension and fatty liver: guilty by association?Hepatocellular Necrosis Associated With Labetalol'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspectiveLabetalolDrug-Induced Liver InjuryHepatotoxicidad secundaria a fármacos de uso comúnRole of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity5-(1-Hydroxy-2-((1-Methyl-3-Phenyl-Propyl)Amino)Ethyl)Salicylamide Hydrochloride 32780-64-6Improving Clinical Risk/Benefit Through StereochemistryHepatitis tóxica en gestante por labetalolAdjunct drugs in liver transplantationThe rational use of potentially hepatotoxic medications in patients with underlying liver diseaseClinical pharmacology of antihypertensive drugsLabetalol-Induced Hepatitis in a Patient With Chronic Hepatitis B InfectionAntihypertensive DrugsDo single enantiomers have something special to offer?DRUG-INDUCED LIVER DISEASEEnantiomer separation of pharmaceuticals by capillary gas chromatography with novel chiral stationary phasesImpact of Geographic and Cross-Cultural Differences on Spontaneous Adverse Events ReportingStereoselectivity of drug actionHepatotoxicity of Cardiovascular DrugsHEPATOTOXICITY OF ANTICHOLESTEROL, CARDIOVASCULAR, AND ENDOCRINE DRUGS AND HORMONAL AGENTSHepatic dysfunction associated with atenololThe cost benefit ratio of enantiomeric drugsPostmarketing Surveillance: Curriculum for the Clinical Pharmacologist. Part II: Clinical and Regulatory ConsiderationsConjonctivite et œdème des paupières par allergie de contact à quatre bêta-bloquants utilisés en collyresSafety Signals from Adverse Drug Experience Reports at FDA: Part IIAspects actuels des risques des médicaments anti-hypertenseurs en immuno-allergologieEffects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.Drugs and Liver DiseaseIdiosyncratic drug reactions: a mechanistic evaluation of risk factors.Hypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated HepatitisDrug Information Analysis ServiceIntravenously administered labetalol for treatment of hypertension in childrenβ-adrenoceptor antagonists and antianginal drugsStereospecific gas chromatographic/mass spectrometric assay of the chiral labetalol metabolite 3-amino-1-phenylbutaneClinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.Labetalol HepatotoxicityEric L. Michelson, MDβ-adrenoceptor antagonists and antianginal drugsCorrection: Labetalol ToxicityBeta-BlockersCardiac Drugs During Pregnancy and LactationHypertension 1 August 1990Volume 113, Issue 3Page: 210-213KeywordsArmed forcesBiostatisticsDrugsEpidemiologyFood and Drug AdministrationLiverMedical risk factorsNecrosisPathogensResearch laboratories Issue Published: 1 August 1990 PDF DownloadLoading ...